|Calculated MW||31.5 kDa|
|Source||(BTI-Tn-5B1-4) Hi-5 Insect cells|
|Sequence||EVLFRCPPCT PERLAACGPP PVAPPAAVAA VAGGARMPCA ELVREPGCGC CSVCARLEGE ACQVYTPRCG QGLRCYPHPG SELPLQALVM GEGTCEKRRD AEYGASPEQV ADNGDDHSEG GLVENHVDST MNMLGGGGSA GRKPLKSGMK ELAVFREKVT EQHRQMGKGG KHHLGLEEPK KLRPPPARTP CQQELDQVLE RISTMRLPDE RGPLEHLYSL HIPNCDKHGL YNLKQCKMSL NGQRGECWCV NPNTGKLIQG APTIRGDPEC HLFYNEQQEA RGVHTQRMQ|
|Application Notes||Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.|
|Storage||-20°C; Sterile filtered through a 0.2 micron filter. Lyophilized from 1 x PBS, pH 7.2.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP2 is a cysteine-rich secreted protein produced by bone cells, and is most abundant in the brain. IGF-BP2 has been shown to inhibit IGF-II action in human breast and ovarian carcinoma cells. Recombinant human IGF-BP2 is a 31.5 kDa protein consisting of 289 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.
Binkert C.,et al.EMBO J. 8:2497-2502(1989).
Zapf J.,et al.J. Biol. Chem. 265:14892-14898(1990).
Ehrenborg E.,et al.Biochem. Biophys. Res. Commun. 176:1250-1255(1991).
Agarwal N.,et al.Exp. Eye Res. 52:549-561(1991).
Binkert C.,et al.Mol. Endocrinol. 6:826-836(1992).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.